Yesterday, on September 30, 2020, I reported that the CareDx AlloSure new LCD had been finalized and was favorable, based on information gleaned from documents inside the Palmetto website (here).
Today, October 1, CMS posted the finalized LCD which will be effective November 15. As predicted yesterday, the title of LCD L38255 was changed from "AlloSure Cell Free DNA Testing" to "AlloSure or Equivalent Cell-Free DNA Testing."
Cloud Zip File
CMS normally posts new LCDs on a public database on Thursday mornings.
CareDx shares have doubled in six months, from about $20 to about $41. The market cap is about $2B, so today's 11% bump was worth about $200m. Six month chart below.
But Wait, There's More: One Open Puzzle